Surveillance data released yesterday by the Centers for Disease Control and Prevention (CDC) show that rates of meningococcal disease have risen sharply in the United States since 2021 and now exceed pre–COVID-19 levels.
A total of 438 confirmed and probable cases of meningococcal disease were reported in 2023, the most US cases reported since 2013. The increase has been driven primarily by Neisseria meningitidis serogroup Y, which is disproportionately affecting Black people, adults between the ages of 30 and 60, and those with HIV. Serogroup Y is one of four N meningitidis serogroups (B, C, and W are the others) that cause most meningococcal disease cases in the United States.
A recent study published in Morbidity and Mortality Weekly Reports described an outbreak of N meningitidis serogroup Y infections in Virginia from 2022 to 2024 in which 80% of cases were in Black residents and 63.9% in residents aged 30 to 60 years.
A rare but severe disease
Meningococcal disease is a rare but severe illness that most often presents as meningitis, with symptoms that may include fever, headache, stiff neck, vomiting, and altered mental status. It can worsen rapidly and become deadly within hours. Even with appropriate antibiotic treatment, the case-fatality rate is 10% to 15%. Prior to 2021, meningococcal disease incidence in the United States had been falling.
In March, the CDC issued a health advisory to alert healthcare providers to the increase in cases, advising them to have heightened awareness of meningococcal disease, particularly among disproportionately affected groups, and to be aware that some patients might present without symptoms typical of meningitis.
The advisory also urged providers to ensure that everyone who's recommended to receive meningococcal vaccination is up to date. The CDC recommends meningococcal vaccination for all adolescents and for children and adults who are at increased risk for meningococcal disease.